Clinical Trials Browser

Cytokine Release Syndrome, Multiple Myeloma

NCT07499128 2026-04-22

Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event

LymphoidOther hematologic neoplasmPlasma cell

Cytokine Release Syndrome, Lymphoma, Multiple Myeloma, Neoplasms, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07390071 2026-02-05

Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy

Phase NA Recruiting

40 enrolled

LymphoidPlasma cell

Cytokine Release Syndrome, Lymphoma, Neoplasms, Plasma Cell

NCT06421675 2025-11-14

EMBRACE

Phase 2 Recruiting

40 enrolled

Plasma cell

Cytokine Release Syndrome, Multiple Myeloma, Recurrence

NCT04975555 2025-09-22

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

Phase 2 Active not recruiting

30 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Cytokine Release Syndrome, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07106671 2025-08-06

A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma

Phase 2 Recruiting

20 enrolled

Plasma cell

Cytokine Release Syndrome, Neoplasms, Plasma Cell

NCT06352866 2025-03-03

Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM

Phase 2 Withdrawn

Plasma cell

Cytokine Release Syndrome, Multiple Myeloma

NCT05414162 2022-06-15

Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy

Unknown

60 enrolled

LymphoidPlasma cell

Cytokine Release Syndrome, Lymphoma, Follicular, Multiple Myeloma, Myocarditis

Clinical Trials

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event

Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy

EMBRACE

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma

Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM

Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy